Treprostinil Prodrugs via Esterification for Pulmonary Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostacyclin therapies for pulmonary hypertension are associated with severe toxicity, tolerability issues, and inconvenient dosing schedules.
Innovation Solution
Development of treprostinil prodrugs and derivatives with ester or amide linkages, which provide less toxicity, better tolerability, and more convenient dosing schedules, manufactured using methods such as esterification and amide functionalization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current prostacyclin therapies are used for pulmonary hypertension, then treatment efficacy is achieved, but severe toxicity and tolerability issues occur
Solution Approach 1:
The prostacyclin molecule is segmented by converting it into a prodrug form with ester or amide linkages. This segmentation modifies the molecular structure to reduce toxicity while maintaining the core therapeutic functionality, allowing the drug to be activated selectively in the body
Solution Approach 2:
The chemical parameters of the prostacyclin are changed by introducing ester or amide functional groups to create prodrug derivatives. These parameter changes alter the pharmacological properties, reducing side effects while preserving the ability to treat pulmonary hypertension effectively
2Reliability
If current prostacyclin therapies are administered, then pulmonary hypertension is treated, but inconvenient dosing schedules are required
Solution Approach 1:
The prostacyclin is prepared in advance as a prodrug with extended half-life characteristics. This preliminary formulation allows the drug to maintain therapeutic levels for longer periods, enabling less frequent dosing schedules while ensuring continuous treatment efficacy
Solution Approach 2:
The dosing regimen is made dynamic by developing prodrugs with optimized pharmacokinetic profiles. The ester and amide derivatives exhibit extended circulation times and controlled release characteristics, allowing flexibility in dosing frequency while maintaining therapeutic effectiveness
3Object-affected harmful factors
If treprostinil prodrugs with ester or amide linkages are developed, then toxicity is reduced and dosing convenience is improved, but manufacturing complexity increases
Solution Approach 1:
The manufacturing process is designed to be universal by using standard esterification and amide coupling reactions that can be applied to multiple prodrug derivatives. This multi-functional approach allows the same core synthesis platform to produce various ester and amide derivatives, reducing overall manufacturing complexity
Solution Approach 2:
Standardized chemical intermediaries with ester or amide functional groups are used as mediators in the synthesis process. These intermediate building blocks simplify the manufacturing of different prodrug derivatives by providing a common starting point that can be efficiently converted into various final products
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treprostinil prodrugs and derivatives offer effective treatment for pulmonary hypertension with reduced side effects and improved dosing convenience, allowing for once-daily or less frequent administration with equal or greater efficacy compared to treprostinil.
Implementation Method 1
a carboxylic acid group is esterified by mixing the appropriate alcohol with treprostinil or a compound of the formula (II) in the presence of an acid catalyst
Implementation Method 2
a carboxylic acid group is converted to an amide with an appropriate amine
Data Source
AI summary
Methods for making prodrugs of treprostinil and treprostinil derivatives are provided. Specifically, methods are provided herein for producing prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide). The linkage, in one embodiment, is via an amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. The compounds provided herein can be used to treat pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension.